SEARCH:      Monitor Keywords |  Custom RSS

Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof January recently filed with US Patent Office 01/12

20120022227 - Radiolabelling reagents and methods: The present invention relates to reagents and methods for [18F]-fluorination of biomolecules, particularly of peptides. The resultant 18F-labelled compounds are useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET).... Agent:

20120022228 - Purification of amphoteric products, or of products liable to be converted into amphoteric products: A process for purifying at least one product from a substrate containing at least one product, includes subjecting the substrate to centrifugal partition chromatography in an ion exchange displacement mode to purify the at least one product from the substrate, the at least one product being an amphoteric product.... Agent: Universite De Reims Champagne-ardenne

20120022229 - Compounds and methods for the treatment of cancer: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.... Agent: Ziopharm Oncology, Inc.

20120022230 - Ionizable isotopic labeling reagents for relative quantification by mass spectrometry: Relative quantification of metabolites by Electrospray Ionization Mass Spectrometry (ESI-MS) requiring a mechanism for simultaneous analysis of multiple analytes in two or more samples. Labeling reagents that are reactive to particular compound classes and differ only in their isotopic compositions facilitate relative quantification. Heavy and light isotopic forms of methylacetimidate... Agent: Wisconsin Alumni Research Foundation

20120022231 - Method for manufacturing cubic diamond nanocrystals: A method for manufacturing cubic diamond nanocrystals (10) comprising the following successive steps: (a) providing crystalline diamond powder where the maximum particle size of the powder is equal or more than 2 um and equal or less than 1 mm; (b) milling said crystalline micron diamond powder using nitrogen jet... Agent:

20120022232 - Cells for increased protein expression comprising one or more release factors and methods of use: The invention provides recombinant cells or recombinant restrictive cells for overexpressing one or more proteins comprising one or more release factors. The invention also provides methods for producing a recombinant protein comprising culturing the cells of the present invention under conditions such that one or more proteins are overexpressed, and... Agent: The Johns Hopkins University

20120022233 - Collagen implant: The invention relates to a highly pure collagen, its use as an implant and a method for its preparation, the method comprising subjecting a sample comprising collagen to at least one alkaline treatment step in an alkaline solution at a pH>12 and at least one cleaning step with at least... Agent:

20120022234 - Method for the purification of albumin conjugates: The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration;... Agent:

20120022235 - Promoter molecules for use in plants: The present invention relates to polynucleotide molecules for regulating gene expression in plants. In particular, the present invention relates to promoters isolated from Brassica napus that are useful for regulating gene expression of heterologous polynucleotide molecules in plants. The present invention also relates to expression constructs and transgenic plants containing... Agent:

20120022238 - Effector function enhanced recombinant antibody composition: Disclosed are a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an... Agent: Kyowa Hakko Kirin Co., Ltd

20120022237 - Peptides for treatment and diagnosis of bone diseases: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to... Agent:

20120022236 - Recombinant anti-vla4 antibody molecules: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites... Agent: Biogen Idec Ma Inc.

20120022239 - Precipitation of biomolecules with negatively charged polymers: The present invention relates to methods of isolating biomolecules. More particularly, the invention relates to methods for isolating antibodies (mAbs) and related proteins including antibody fragments (Fabs) under conditions where they are positive and relatively hydrophobic and will react with negatively charged polymer to form polymer-protein complexes which precipitate. The... Agent: Ge Healthcare Bio-sciences Ab

20120022240 - Lignin preparations isolated from plant material, and methods for their isolation and use: Lignin polymers having distinctive properties, including a generally high molecular weight and generally homogeneous size distribution, as well as preservation of native reactive side groups, are isolated by solvent extraction of plant materials. Methods for isolation of lignin polymers, and for use of the isolated lignin polymers are disclosed. Compositions... Agent: Vertichem Corporation

20120016102 - Non-toxic biofilm inhibitor: The present invention relates to a composition, device and method for preventing or inhibiting biofilm formation on biotic or abiotic surfaces. The composition comprises a peptide based on the C-terminal receptor binding domain of Pseudomonas aeruginosa type IV pilin, which binds to an abiotic surface (e.g., steel, plastic) with high... Agent: The Regents Of The University Of Colorado, A Body Corporate

20120016103 - Pepstatin a derivatives: The invention relates to a compound having a structure according to the general formula P3-P2-P1-P1′-P2′ (I), wherein residues P3, P2, P1, P1′ and P2′ are specifically defined and may be, e.g., certain amino acid residues. The invention further relates to the use of said compound and to a method for... Agent: Freie Universitaet Berlin

20120016104 - Glycosylated il-7, preparation and uses: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified... Agent: Cytheris

20120016105 - Purification of peptide conjugates by hydrophobic interaction chromatography: The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue... Agent: Novo Nordisk A/s

20120016106 - Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8 associated disorders: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of... Agent: Wyeth LLC

20120016108 - Compositions and methods for treating kidney disease: The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage.... Agent:

20120016107 - Growth factor htter36: The present invention discloses Growth Factor HTTER36 (GDF3) polypeptides and polynucleotides encoding such polypeptides. Also provided are antibodies that bind HTTER36, including chimeric, humanized, and single chain antibodies.... Agent: Human Genome Sciences, Inc.

20120016109 - Estrogen receptors and methods of use: The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity... Agent: Creighton University

20120016110 - Method of immobilizing and stretching a nucleic acid on a substrate: The present invention relates to a method of immobilizing and stretching a nucleic acid on a silicon substrate, to nucleic acids and substrates prepared according to this method, to uses of the method and to uses of the nucleic acid and the substrate.... Agent:

20120016111 - Compositions for the treatment of cancer, and methods for testing and using the same: A composition comprising leukotoxin proteins isolated from a bacterium is provided. In this composition, greater than 85% of the leukotoxin proteins are chemically modified at a basic amino acid residue, and the proteins induce cell death in myeloid leukocytes, while remaining substantially non-toxic to lymphoid leukocytes, lymphocytes, and red blood... Agent: University Of Medicine And Dentistry Of New Jersey

20120016112 - Processing of macronutrients: The present invention generally relates to edible compositions and methods to produce them. In particular, the present invention relates to the enzymatic modulation of macron utrients and to food compositions containing such modulated macronutrients. One embodiment of the present invention is a method for modulating macronutrients comprising the steps of... Agent: Nestec S.a.

20120016113 - Buoyant protein harvesting device: A buoyant device containing chromatography media performs the function of protein harvesting replacing the steps of cell separation and volume reduction; the device can be loaded into columns for further purification.... Agent: Therapeutic Proteins Inc

20120010384 - Epitope synchronization in antigen presenting cells: Disclosed herein are vaccines and methods for inducing an immune response against cancer cells and cells infected with intracellular parasites. Vaccines having housekeeping epitopes are disclosed. The housekeeping epitope is formed by housekeeping proteasomes in peripheral cells, but not by professional antigen presenting cells. A vaccine containing a housekeeping epitope... Agent: Mannkind Corporation

20120010386 - Recombinant melusin fusion protein as pharmacological agent in the treatment of heart pathologies and compositions thereof: A recombinant melusin fusion protein having an improved stability and a capability to reach intracellular compartments as compared to recombinant melusin in vivo, wherein said protein comprises i) a human melusin protein having the amino acid sequence as defined in SEQ ID No.:1, or a homologue thereof having at least... Agent: Target Heart Biotec S.r.l.

20120010385 - Splice variants of human g-protein coupled receptor hgprbmy29 (hgprmby29sv2): The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors,... Agent: Bristol-myers Squibb Company

20120010387 - Antibody variants composition: Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues... Agent: Kyowa Hakko Kirin Co., Ltd.

20120010388 - Ley specific biotherapeutic: Embodiments are related to the field of immunology, and provide a highly avid LeY specific biotherapeutic including at least one further binding site having a different specificity to bind an epitope of a glycosylated cell surface molecule of a tumor cell, characterized by EC50 of less than 1 mM to... Agent:

20120010389 - Detection of specific nitrated markers: Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to... Agent: Universite De Liege

20120010390 - Separation method using single polymer phase systems: The present invention relates to a process of enriching one target compound from a liquid, which process comprises at least one step of isolation performed by differentially partitioning between two aqueous phases. In the present invention the phases are formed by adding a thermally responsive, self-associating (i.e. clouding) hydrophilic polymer,... Agent: Ge Healthcare Bio-sciences Ab

20120004389 - Method for extracting propolis using far-infrared rays from earthenware: A method for extracting propolis by using far infrared ray from pottery. The method for extracting propolis by using far infrared ray from pottery makes it possible to prohibit the growth of microorganism by way of far infrared ray by using pottery which emits far infrared ray and has a... Agent:

20120004390 - Preparation method of pimaric acid type resin acid: A method for preparing pimaric acid type resin acids includes the following steps: step (1) adding refined resin acid, turpentine, or rosin along with maleic anhydride at a mass ratio of 1:0.3-1.5 into a reaction bottle, dissolving the ingredients into a C1-C10 lower fatty acid solvent, the mass ratio of... Agent:

20120004391 - Cyanine-type compounds having an alkynyl linker arm: Cyanine-type fluorescent dyes modified with an alkynyl linker arm of formula (I), suitable for the conjugation of biomolecules, such as for example nucleosides, nucleotides, oligonucleotides, nucleic acids, proteins, peptides, vitamins and hormones. A method and intermediates for the synthesis of the alkynyl cyanines of the invention are also described, as... Agent:

20120004394 - Immunosuppressive peptide: a

20120004393 - Potent compstatin analogs: Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.... Agent:

20120004392 - Selective glucagon-like-peptide-2 (glp-2) analogues: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions (11, 16, 20, 24) and/or (28) of... Agent: Zealand Pharma A/s

20120004395 - Use of serine protease inhibitors in the treatment of neutropenia: The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in... Agent: Med Discovery Sa

20120004396 - Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin: The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to auto oxidation and superior oxygen carrying characteristics.... Agent: Sangart, Inc.

20120004397 - Violet laser excitable dyes and their method of use: The present invention provides dye compounds optimally excited at about 400 nm and have a Stokes shift of at least about 80 nm. These dyes find use in detection of analyte in a sample and the preparation of dye-conjugates.... Agent: Life Technologies Corporation

20120004398 - Method for uses of protein precursors as prodrugs: The present invention provides compositions useful as prodrugs and methods for making the same. The compositions include a fusion protein having a first delivery domain and a second protein precursor domain linked together via a linker sequence. The delivery domain is a protein capable of facilitating entry to a target... Agent: University Of Southern California

20120004399 - Isolated egg protein and egg lipid materials, and methods for producing the same: A method for separating proteins and fats from an egg mixture is disclosed herein. The method includes a step of microfiltration of the egg mixture, wherein microfiltration includes pumping across a filter an egg mixture containing egg yolk and egg whites (albumen). An egg powder obtained from egg and a... Agent: Rembrandt Enterprises, Inc.